<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> is an <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> characterized by the presence of circulating <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) that promote <z:mp ids='MP_0005048'>thrombosis</z:mp>, <z:e sem="disease" ids="C0032962" disease_type="Disease or Syndrome" abbrv="">pregnancy complications</z:e> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Alterations in the function of vascular cells induced by aPL underlie these outcomes </plain></SENT>
<SENT sid="2" pm="."><plain>This review will discuss recent findings that indicate a novel mechanism by which aPL antagonize endothelial cell production of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> and thereby promote <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
</text></document>